RXDX News

A total of 32 companies entered the public market this past week, with the week’s 7 IPOs joined by one direct listing and 24 SPACs. In the largest US IPO of the year to date, Coupang (CPNG) upsized and priced above the upwardly revised range to raise $4.6 billion at a $62.9 billion market cap. The largest e-commerce player in Korea, Coupang nearly...read more

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, raised $190 million by offering 10 million shares at $19, the high end of the upwardly revised range of $18 to $19. The company offered 1 million more shares than anticipated. It originally planned to offer 7.4 million shares at $16 to $18, before increasing the deal size...read more

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, raised the proposed deal size for its upcoming IPO on Thursday. The San Diego, CA-based company now plans to raise $167 million by offering 9 million shares at a price range of $18 to $19. The company had previously filed to offer 7.4 million shares at a range of $16...read more

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Prometheus Biosciences would command a fully diluted market value...read more